Ramsay Newsroom

The disease is the most common gynaecological cancer, with 1,900 Australians diagnosed each year.

The study will involve giving stage 4 cancer patients a type of chemotherapy drug, administered intravenously, when other treatments have been exhausted.

Anti-body drug conjugates (ADCs) are a targeted therapy, designed to more precisely locate and kill cancer cells while minimising damage to healthy tissue.

Principal investigator and JHC Oncologist Dr Navin Palayoor will help conduct the phase 3 clinical trial, and said previous studies have shown positive results.

“Some ADCs are already approved to treat other cancers. We hope this trial will reveal less severe side effects compared to traditional chemotherapy for this particular type of cancer,” Dr Palayoor said.

“Although uterine cancer is not the most aggressive gynaecological cancer, it’s frequently diagnosed and numbers are on the rise. If this study is proven successful, it might even become one of the first options of treatment ahead of those with worse side effects.”

The study is one of several cancer research projects underway at JHC.

JHC’s Director of Research Professor Desiree Silva said cancer research is imperative to improving health outcomes for future generations.

“There’s a concerning rise in cancer diagnoses across the board, especially in young people, which is why it’s critical to determine environmental risks and other factors contributing to this increase,” Professor Silva said.

This initiative by JHC, and Ramsay Health Care, demonstrates a strong commitment to advancing cancer care through research and innovation.

This World Cancer Day (4 February), Ramsay Health Care, which is Australia’s largest provider of hospital-based cancer services is releasing a new cancer strategy.
 
The strategy outlines the organisation’s clear ambition to build a more connected, consistent, and research-led cancer care network for Australians.

Ramsay seeks to lead nationally in research and innovation by building connected clinical trial networks and centres of excellence that bring emerging therapies into routine care, supporting better outcomes for patients and contributing to the future of cancer care in Australia.

Media contact: Lindsay Brennan – 0423 387 042